Piramal Enterprises has signed an agreement to sell its Hyderabad-based clinical research division to Indoco Remedies for undisclosed amount.
Piramal Enterprises has signed a definitive agreement to sell its clinical research division known as ‘Piramal Clinical Research’ (PCR) to Indoco Remedies on a going concern basis for cash, the company said in a filing to BSE.
“Fixed assets of this division along with the employees will be transferred to Indoco on a slump sale basis as a part of the transaction,” it added.
The sale transaction is expected to be completed upon receipt of purchase consideration by April 6.
“PCR was not considered strategic in nature and formed a relatively small portion of the PEL’s consolidated business. The transaction does not have a material impact on PEL’s balance sheet or P&L,” it added.
PCR specialises in conducting bioanalytical and bioequivalence studies for generic products and holds approvals from various regulatory agencies, including USFDA, and U.K. MHRA among others, Piramal Enterprises said.
